BioSyent Inc.

BioSyent Inc.

December 13, 2007 17:00 ET

BioSyent Management Announcement

MISSISSAUGA, ONTARIO--(Marketwire - Dec. 13, 2007) - BioSyent Inc. ("BioSyent", the "Company") (TSX VENTURE:RX), is pleased to announce the promotion of Alfred D'Souza to the position of Vice-President, Chief Financial Officer. Mr. D'Souza is a Certified Management Accountant and M.B.A. (Wilfrid Laurier University) who joined BioSyent as Controller and Director of Finance in October 2006. Mr. D'Souza has over 25 years of accounting, finance and operations management experience in international businesses ranging from early stage to rapid growth to mature markets. Prior to joining BioSyent, Mr. D'Souza enjoyed a 16 year career with progressive management assignments at Colgate-Palmolive Company. Mr. D'Souza's last two positions at Colgate-Palmolive were Head of Finance (Country Controller) at Colgate-Palmolive Vietnam while it grew from sales of less than to USD $2 million to over $25 million, and most recently as Finance Director and Controller of Colgate-Palmolive India a publicly traded (BSE) USD $225 million company with 4,000 employees and 6 manufacturing plants in India.

In commenting on the promotion of Mr. D'Souza, Rene Goehrum, President and CEO of BioSyent remarked "We are delighted to have Alfred as part of our senior management team. Alfred's hands-on experience in corporate finance, supply chain management and commercial operations is invaluable as we prepare for the next phase in the growth and development of our business."

The Company also announces the grant of 445,000 incentive stock options to certain directors, officers and employees of the Company. These incentive stock options are exercisable at a price of $0.10 up to December 12, 2012.

BioSyent continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of same.

Contact Information